Cara Therapeutics (CARA) 10-K2019 FY Annual report

Filed: 27 Feb 20, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accretion, agitation, anxiety, assignee, bankrupt, BID, biliary, Black, Buyout, Carolina, Circuit, codified, comparison, Conference, correlate, counterpart, customary, distressing, eating, EBP, embedded, epidemiological, epidermal, excipient, expedient, Foundation, franchise, grantee, Greenville, Harmonization, hepatic, hereof, hindsight, Holdco, ICH, implicit, interplay, invasive, kg, KOR, lawfully, mcg, mediated, Monza, morbidity, Morgan, MSA, Nadsaq, NKF, nurse, official, outbreak, Patheon, PBC, Peptelligence, permanently, permeability, petition, placement, playing, predisposition, prophylactic, prophylactically, psychosocial, recalculated, referenced, remanded, remedy, ROU, roughly, scarcity, screen, signature, skin, solubility, Supplementary, thereon, therewith, thing, true, undiagnosed, unqualified, unregistered, upheld, virtue, voluntarily

Removed: absence, accessed, accrue, acetaminophen, acquired, activate, adjunctive, administer, advancement, Allergan, allocable, amendment, amounted, analog, anandamide, API, asimadoline, assigned, asymptomatic, Avinza, bear, bioavailable, body, bone, bunionectomy, bupivacaine, buy, cancelled, causality, CB, Celebrex, Celgene, characteristic, childbirth, clonidine, College, Collegium, Cumberland, dexmedetomidine, dextromethorphan, discharge, disposed, disqualified, diverse, dominated, Duke, Duragesic, eczema, Egalet, electrocardiogram, Endo, EXALGO, exceeded, exit, expressing, fatigue, fentanyl, France, frequent, Germany, golden, guaranteed, hard, hip, Horizon, hydrochloride, hydrocodone, hydromorphone, hypothermia, ibuprofen, imidazoheterocycle, Importantly, improved, Indemnity, independence, inflammation, internet, Janssen, Joseph, KADIAN, knee, laparoscopic, lidocaine, localized, Mallinckrodt, marked, McMaster, Menzaghi, missing, modulating, morphine, musculoskeletal, naproxen, nascent, neuropathic, nonbinding, NSAID, nucynta, OA, Ontario, Opana, optional, orally, owner, oxycodone, OxyContin, oxymorphone, Pacira, parachute, Parrott, pattern, Percocet, Pernix, PGA, pharmacokinetic, plasma, Plaza, pregabalin, principle, productivity, Purdue, rapid, recognizing, reconciling, relocated, relocation, resolution, restated, sedation, segmented, session, shorter, sixteen, soft, Spain, Stauffer, subset, subside, sulfate, superfamily, surgical, tapentadol, therapeutically, tissue, toxicology, transdermal, undertreated, unimportant, University, urine, vacated, vast, version, Vicodin, visual, Western, widely, WOMAC, write

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated CARA transcripts

CARA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

(1)

Registration Statement (Form S-3ASR No. 333-233666) of Cara Therapeutics, Inc.

(2)

Registration Statement (Form S-3 No. 333-230333) of Cara Therapeutics, Inc.

(3)

Registration Statement (Form S-3 No. 333-216657) of Cara Therapeutics Inc.

(4)

Registration Statement (Form S-8 No. 333-234800) of Cara Therapeutics, Inc., pertaining to the Cara Therapeutics, Inc. 2019 Inducement Plan

(5)

Registration Statement (Form S-8 No. 333-230335) of Cara Therapeutics, Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics Inc.

(6)

Registration Statement (Form S-8 No. 333-223726) of Cara Therapeutics, Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics Inc.

(7)

Registration Statement (Form S-8 No. 333-216606) of Cara Therapeutics Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics Inc.

(8)

Registration Statement (Form S-8 No. 333-210096) of Cara Therapeutics Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics Inc.

(9)

Registration Statement (Form S-8 No. 333-203057) of Cara Therapeutics Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics Inc., and

(10)

Registration Statement (Form S-8 No. 333-193905) pertaining to the 2004 Stock Incentive Plan, as amended, and 2014 Equity Incentive Plan;

of our reports dated February 27, 2020, with respect to the financial statements of Cara Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Cara Therapeutics, Inc. included in this Annual Report (Form 10-K) of Cara Therapeutics Inc., for the year ended December 31, 2019.

/s/ Ernst & Young LLP

Stamford, Connecticut

February 27, 2020

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.